Kaken Pharmaceutical Co., Ltd. (KKPCF)
OTCMKTS · Delayed Price · Currency is USD
26.78
+0.78 (3.00%)
Feb 5, 2026, 4:00 PM EST

Kaken Pharmaceutical Cash Flow Statement

Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '25 Mar '24 Mar '23 Mar '22 Mar '21
Net Income
19,4359,7966,81713,88518,657
Depreciation & Amortization
2,5542,7532,5682,4862,318
Loss (Gain) From Sale of Assets
1,5551671,9112,896-333
Loss (Gain) From Sale of Investments
287-13-1-1-115
Other Operating Activities
-842-3,788-4,407-4,431-5,517
Change in Accounts Receivable
3,577-4,5599723921,251
Change in Inventory
-1,084-1,603-583241-2,923
Change in Accounts Payable
1,100880280-2,630-112
Change in Other Net Operating Assets
3,198-1,0561,6964981,154
Operating Cash Flow
29,7802,5779,25313,33614,380
Operating Cash Flow Growth
1055.61%-72.15%-30.62%-7.26%-47.65%
Capital Expenditures
-4,138-1,861-1,987-2,986-1,973
Sale of Property, Plant & Equipment
-112704874
Cash Acquisitions
-15,378---4,975-
Sale (Purchase) of Intangibles
-254-306-219-271-313
Investment in Securities
120516-1955124
Other Investing Activities
--4,204-238-365-356
Investing Cash Flow
-19,650-5,854-2,627-7,888-1,644
Issuance of Common Stock
7,764----
Repurchase of Common Stock
-5,935--1,340-2,414-2,940
Common Dividends Paid
-7,198-5,657-5,649-5,714-5,811
Other Financing Activities
--1-1-1-1
Financing Cash Flow
-5,369-5,658-6,990-8,129-8,752
Miscellaneous Cash Flow Adjustments
-1--1-1
Net Cash Flow
4,760-8,935-364-2,6803,983
Free Cash Flow
25,6427167,26610,35012,407
Free Cash Flow Growth
3481.28%-90.15%-29.80%-16.58%-50.98%
Free Cash Flow Margin
27.27%0.99%9.96%13.61%16.55%
Free Cash Flow Per Share
671.9218.97193.39272.53321.51
Cash Interest Paid
2817171717
Cash Income Tax Paid
8363,7884,4094,4315,516
Levered Free Cash Flow
22,980-1,2997,4868,0259,418
Unlevered Free Cash Flow
22,998-1,2897,4978,0369,429
Change in Working Capital
6,791-6,3382,365-1,499-630
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.